SCHEMBL6426067

SCHEMBL6426067

O=C1N=C(NCCc2ccccc2)SC1CC(=O)N1CCCc2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
KMT2A Q03164 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
TSHR P16473 3/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
NFKB1 P19838 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MEN1 O00255 1/20 0.43
GRM7 Q14831 2/20 0.43
ALDH1A1 P00352 6/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
GAA P10253 2/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427089 0.87 OPRM1 (0.44) KDM4EKMT2ASMN1; SMN2TSHRMAPK1
SCHEMBL6428309 0.85 GRM7 (0.46) KDM4ESMN1; SMN2TSHRMAPTMAPK1
SCHEMBL6427179 0.84 ALDH1A1 (0.51) KDM4EKMT2ASMN1; SMN2TSHRMAPT
SCHEMBL1605788 0.83 TSHR (0.46) KDM4ESMN1; SMN2TSHRNPC1MAPT
SCHEMBL6428624 0.82 GRM7 (0.45) KMT2ASMN1; SMN2TSHRMAPTGRM7
SCHEMBL6502545 0.81 TSHR (0.53) KDM4EKMT2ASMN1; SMN2TSHRNPC1
SCHEMBL6500660 0.81 TSHR (0.53) KDM4EKMT2ASMN1; SMN2TSHRNPC1
SCHEMBL6506436 0.81 TSHR (0.53) KDM4EKMT2ASMN1; SMN2TSHRNPC1
SCHEMBL6426299 0.80 GRM7 (0.46) KMT2ASMN1; SMN2TSHRMAPTMAPK1
SCHEMBL6508360 0.80 ALDH1A1 (0.47) KDM4EKMT2ASMN1; SMN2TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 KDM4E 2824/4885KMT2A 3213/4885SMN1; SMN2 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.